Meeting Details - The shareholder meeting was held on January 15, 2026, at the company's conference room located at 488 Huixian Road, Jiading District, Shanghai [1] - The meeting was attended by 7 current directors, with 6 present and one independent director, Mr. Huan Anan, absent due to personal reasons [2] Voting and Resolutions - A resolution regarding the completion of certain fundraising investment projects and the permanent allocation of surplus funds to replenish working capital was approved [3] - All resolutions were ordinary voting matters and were passed with more than half of the valid voting rights held by attending shareholders or their representatives [3] Legal Compliance - The meeting was witnessed by Shanghai Guangfa Law Firm, with lawyers Shi Min and Li Lingling present [4] - The legal opinion concluded that the procedures for convening and holding the meeting complied with the Company Law, Shareholders' Meeting Rules, and other relevant regulations, ensuring the legality of the meeting's conveners and attendees [4]

Core Viewpoint - Longyuan Power Group Co., Ltd. has successfully completed the issuance of its second phase of ultra-short-term financing bonds for 2026, aimed at supplementing working capital and repaying interest-bearing debts of the issuer and its subsidiaries [2][5]. Group 1 - The company received authorization from its shareholders on June 17, 2025, to apply for and issue debt financing instruments with a total new scale not exceeding RMB 500 billion (including 500 billion) [1][4]. - The company can register debt financing instruments with the China Interbank Market Dealers Association, with a total new scale not exceeding RMB 800 billion (including 800 billion), and may issue them in installments [1][4]. - The relevant documents for the bond issuance have been published on the China Money website and the Shanghai Clearing House website [2][6]. Group 2 - The first phase of ultra-short-term financing bonds for 2026 was also successfully issued on January 14, 2026, with similar purposes for the raised funds [5][6]. - The company’s board of directors has been authorized to handle related matters within the scope of the authorization granted by the shareholders [1][4].

登录新浪财经APP 搜索【信披】查看更多考评等级 1．重庆长安汽车股份有限公司（以下简称"公司"）本次回购注销原32名激励对象已获授但尚未解除限 售的A股限制性股票共1,161,948股，占回购注销前公司总股本的0.01%。 2．中国证券登记结算有限责任公司深圳分公司确认已于2026年1月15日办理完成公司本次部分限制性股 票回购注销事宜。本次注销符合法律、行政法规、部门规章、规范性文件、公司章程、股权激励计划等 的相关规定。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 3．本次回购注销完成后，公司总股本由9,914,086,060股减少至9,912,924,112股。 公司于2025年9月26日召开第九届董事会第四十五次会议，并于2025年10月24日召开2025年第一次临时 股东大会，审议通过了《关于调整A股限制性股票激励计划回购价格及回购注销部分限制性股票的议 案》。详细内容见2025年9月27日披露在巨潮资讯网（www.cninfo.com.cn）及《中国证券报》《证券时 报》《证券日报》《上海证券报》的《关于调整A股限制性股票激励计划 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司高级管理人员王文旭先生保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 山东三维化学集团股份有限公司（以下简称"公司"）于2025年9月16日在《中国证券报》、《证券时 报》及巨潮资讯网（http://www.cninfo.com.cn）披露了《关于高级管理人员减持股份的预披露公告》 （公告编号：2025-031），公司高级管理人员王文旭先生计划自上述公告披露之日起15个交易日后的3 个月内（2025年10月16日至2026年1月15日，窗口期内不得减持）以集中竞价交易方式减持其持有的本 公司股份不超过120,656股（占本公司总股本的比例不超过0.0186%）。 近日，公司收到王文旭先生发来的《股份减持计划实施结果的告知函》，截至本公告披露日，王文旭先 生本次股份减持计划期限已届满，现将具体实施结果公告如下： 一、股东减持情况 1、股东减持股份情况 ■ 注：本表中的"比例"系四舍五入后保留四位小数的结果。 王文旭先生本次减持的股份来源于公司股权激励计划 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002361 证券简称：神剑股份 编号：2026-001 安徽神剑新材料股份有限公司 第六届董事会第十四次会议决议公告 公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导性陈述或者重大遗漏。 安徽神剑新材料股份有限公司（以下简称"公司"）第六届董事会第十四次会议于2026年1月4日以电子邮 件或传真的形式发出会议通知，2026年1月15日以现场及通讯表决的方式召开。 会议应参会董事7名，实际参会董事7名。会议在保证所有董事充分发表意见的前提下，以现场填写表决 票的方式审议表决。 本次会议的召集、召开和表决程序符合《公司法》、《公司章程》等有关规定。会议由董事长王津华先 生主持。 特此公告。 鉴于公司第六届董事会任期届满，根据《公司章程》的有关规定，公司第七届董事会拟由7名董事组 成。其中非独立董事4名，独立董事3名。 经与会董事表决，通过如下决议： 一、会议以赞成票7票，反对票0票，弃权票0票，审议通过了《关于提名第七届董事会非独立董事候选 人的议案》。 本次会议同意提名王津华先生、吴昌国先生、高韡先生、曹灿灿女士为公司第七届董事会 ...

Group 1 - The company reported a total new contract amount of RMB 1,468.16 billion for the year 2025, with the construction business contributing RMB 1,164.28 billion [2] - The company signed several large construction contracts from October to December 2025, each exceeding RMB 1 billion [3] Group 2 - The company announced the resignation of Vice General Manager Liu Jianwei due to work adjustments, who will continue to hold other positions within the company [4] - Liu Jianwei did not hold any company stock and there are no unfulfilled commitments that would affect the company's normal operations [4]

Core Viewpoint - The company plans to repurchase and cancel a total of 4,552,410 shares of restricted stock due to the departure of certain incentive plan participants and unmet performance targets for the second release period of the stock [2][9]. Group 1: Reasons for Repurchase and Cancellation - The repurchase and cancellation are due to 8 individuals leaving for personal reasons and 2 retiring, which disqualifies them from being incentive plan participants [2][10]. - Additionally, the company did not meet the performance assessment criteria for the second release period, leading to the cancellation of 4,329,270 shares of restricted stock [8][10]. Group 2: Decision and Disclosure Process - The decision for the repurchase was approved in meetings held on September 25, 2023, and subsequent meetings, with independent directors providing opinions and the supervisory board verifying the matters [3][4]. - The company publicly disclosed the names and positions of the incentive plan participants from September 26 to October 6, 2023, with no objections received during the public notice period [3][4]. Group 3: Repurchase and Cancellation Details - The repurchase involves a total of 421 participants, with 10 disqualified due to personal reasons and 411 due to unmet performance targets [10]. - The company has set up a dedicated securities account for the repurchase and expects to complete the cancellation by January 20, 2026 [11]. Group 4: Changes in Share Structure - Following the cancellation, the company's share capital will be adjusted, with the total number of shares decreasing from 2,400,227,363 to 2,379,001,490 [18][19]. Group 5: Legal Compliance and Commitments - The board assures that the decision-making process and disclosures comply with relevant laws and regulations, and there are no violations of the rights of incentive participants or creditors [13][14].

证券代码：600989 证券简称：宝丰能源 公告编号：2026-003 宁夏宝丰能源集团股份有限公司 股份质押公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示: ●截至2025年末，宁夏宝丰能源集团股份有限公司（以下简称"公司"）实际控制人党彦宝先生持有公司 股份552,000,000股，占公司总股本的7.53%。本次质押后，累计质押公司股份141,810,000股，占其所持 公司股份的25.69%，占公司总股本的1.93%。 一、上市公司股份质押 公司于2026年1月14日接到实际控制人党彦宝先生通知，获悉其所持有本公司的部分股份被质押，具体 情况如下。 1.本次股份质押基本情况 2026年1月14日，党彦宝先生与中国银河证券股份有限公司（以下简称"银河证券"）办理了股票质押业 务，将部分无限售条件流通股股份质押给银河证券。具体情况如下： 2.本次质押股份不涉及用作重大资产重组业绩补偿等事项的担保或其他保障用途的情况。 3.股东累计质押股份情况 截至公告披露日，上述股东及其一致行动人累计质押股份情况如下： ...

Group 1 - The company held its first extraordinary general meeting of shareholders on January 15, 2026, where it approved the change of the fundraising project from "Headquarters R&D Center Construction Project" to "Machine Vision Intelligent Manufacturing Expansion Project" [1][2] - To regulate the management and use of raised funds and protect investors' rights, the company decided to open a special account for the "Machine Vision Intelligent Manufacturing Expansion Project" and sign a supervision agreement with the sponsoring institution and the supervising bank [2] - The board of directors authorized the general manager or designated personnel to handle the opening of the special bank account and the signing of the supervision agreement [2] Group 2 - The extraordinary general meeting was convened in accordance with legal and regulatory requirements, and the voting process was compliant with the Company Law and the company's articles of association [6][7] - There were no rejected proposals during the meeting, and the meeting was attended by all seven current directors and the board secretary [5][7] - The meeting was witnessed by a law firm, which confirmed that the convening and voting procedures were legal and valid [6][7]

Core Viewpoint - Zhejiang Jianfeng Group Co., Ltd. announced that its subsidiary, Jianfeng Pharmaceutical, has voluntarily withdrawn the clinical trial application for the drug "C2235 and C2235 tablets" to the National Medical Products Administration, pending further research and will resubmit the application at a later date [2][3]. Group 1: Drug Registration and Withdrawal - Jianfeng Pharmaceutical received a termination notice for the drug registration application for "C2235 and C2235 tablets" from the National Medical Products Administration, indicating that the withdrawal was a proactive decision by the company [2]. - The withdrawal was due to the need for further improvement of the application materials during the registration process [2]. Group 2: Impact on Company Performance - The withdrawal of the clinical trial application for "C2235 and C2235 tablets" is not expected to have a significant impact on the company's current performance [3]. - The company acknowledges that the research and development of innovative drugs involve high technology and risks, with long and complex cycles from development to production, which are susceptible to unpredictable factors [3].